These medications mimic natural gut hormones that signal fullness to the brain, helping patients break cycles of overeating
Search words included: GLP-1, Glucagon-Like Peptide 1, semaglutide, oral semaglutide, Rybelsus, Ozempic, liraglutide, lixisenatide, dulaglutide, albiglutide, exenatide, DPP4 inhibitor, dipeptidyl phosphatase 4 inhibitor, sitagliptin, antidiabetics, metformin, insulin, type 2 diabetes, diabetes, diabetes mellitus, neurodegenerative diseases, glaucoma, AMD, age-related macular degeneration, diabetic retinopathy, elderly, Alzheimer, dementia, cognitive impairment, Alzheimers Disease, Parkinson, Parkinsons Disease, stroke, neuropathy
Clinical trials have not confirmed this as a common potential side effect, but anecdotal reports from the National Library of Medicine suggest it may affect a subset of patients
Not for human consumption, therapeutic application, or veterinary use